WFA
FMTX

Wipfli Financial Advisors’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Wipfli Financial Advisors’s Portfolio FMTX Stock Details FMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$16K Buy
+800
New +$10.6K ﹤0.01% 1674

Other funds holding FMTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Wipfli Financial Advisors's FMTX Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q3 2022: 800 shares worth $16K. The stake represents ﹤0.01% of the portfolio and ranks #1674 among its holdings.

139 funds tracked by Wall St. Rank hold FMTX as of Q3 2022.

  • Wipfli Financial Advisors held 800 shares of Forma Therapeutics Holdings, Inc. Common Stock worth $16K as of Q3 2022.
  • Forma Therapeutics Holdings, Inc. Common Stock was a new Wipfli Financial Advisors position in Q3 2022.
  • Forma Therapeutics Holdings, Inc. Common Stock made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1674 holding.
  • 139 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.